drugset
drugset / Trial / NCT05281003

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

NCT05281003 ↗

Phase 2 Recruiting 128 enrolled Fudan University Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and paclitaxel as neoadjuvant treatment in participants with locally advanced esophageal squamous cell carcinoma (ESCC), and to explore treatment resistance mechanisms.

Timeline

Start
2023-02-20
Primary completion
2023-09-01
Completion
2026-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 80 mg/m2 Intravenous
Subject Paclitaxel Small molecule 150 mg/m2 Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

esophageal squamous cell carcinoma